Last10K.com

Bovie Medical Corp (BVX) SEC Filing 8-K Material Event for the period ending Wednesday, August 1, 2018

Bovie Medical Corp

CIK: 719135 Ticker: BVX
a2017bvxlogoa04.jpg
 

EXHIBIT 99.1

Bovie Medical Corporation Reports Second Quarter 2018 Financial Results
Advanced Energy Sales of $3.1 million in Q2, up 72% year-over-year

CLEARWATER, FL — AUGUST 1, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its second quarter ended June 30, 2018.

Second Quarter 2018 Financial Summary:

Total Q2 revenue of approximately $11.5 million, up 17% year-over-year.
Advanced Energy revenue of $3.1 million, up 72% year-over-year, driven by strong J-Plasma/Renuvion sales.
Core revenue of approximately $7.8 million, up 4% year-over-year.
OEM revenue of approximately $0.6 million, up 16% year-over-year.
Total Q2 adjusted EBITDA of approximately $0.3 million versus adjusted EBITDA loss of approximately $0.9 million for the second quarter of 2017.

Second Quarter 2018 Operating Highlights:

On May 1st, the Company announced the appointment of Diane I. Duncan, M.D., FACS, a Board-certified plastic surgeon, to the Company’s Medical Advisory Board.
On May 14th, the Company announced the completion of enrollment in the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing.

Operating Highlights Subsequent to Quarter-End:

On July 9th, the Company announced it has entered into a definitive agreement with Specialty Surgical Instrumentation Inc., a subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company will divest and sell the Core business segment and the Bovie® brand to Symmetry for gross proceeds of $97 million in cash. The asset purchase agreement was approved by the Company’s Board of Directors and is subject to customary closing conditions - including approval by the Company’s stockholders. The transaction is expected to close in the third quarter of 2018.

Annual Stockholders’ Meeting:

The Annual Meeting is scheduled to be held on August 30, 2018 at 10:00 a.m. Eastern Standard Time at the offices of Ruskin Moscou Faltischek, P.C., located at East Tower, 15th Floor, 1425 RXR Plaza, Uniondale, New York 11556.



a2017bvxlogoa04.jpg
 
 

Management Comments:

“Bovie Medical is pleased to report another quarter of impressive financial performance and exciting operational progress,” said Charlie Goodwin, Chief Executive Officer. “We experienced strong growth in our Advanced Energy business, which was marked by continued strength in both adoption and utilization of our J-Plasma/Renuvion technology. The trends we saw in our Advanced Energy business continue to confirm our strategic focus on the U.S. cosmetic surgery market, where our hybrid sales force is driving adoption of our Renuvion Cosmetic Technology. Building on the strong Advanced Energy growth in the U.S., we also saw strong demand for our J-Plasma/Renuvion technology from our network of distribution partners outside the U.S. in the second quarter.”

Mr. Goodwin continued: “We complemented our second quarter financial performance by achieving a number of important operational milestones related to our longer-term growth strategy to create a foundation of support for our Renuvion technology that will encourage its broader adoption in the cosmetic surgery market going forward. Specifically, we completed enrollment in our U.S. IDE clinical study evaluating the use of Renuvion Technology for dermal resurfacing procedures. This study represents an exciting first step in our efforts to establish strong clinical support demonstrating the positive outcomes that can be achieved by using Renuvion technology. Furthermore, the results from the dermal resurfacing U.S. IDE clinical study will support our 510(k) submission to the FDA for a new indication to market and sell Renuvion for dermal resurfacing procedures.”

“We also made progress towards our strategic goal of enhancing physician and practice support for our cosmetic surgery customers with the launch of Renuvion Cosmetic Technology, a new dedicated brand for our J-Plasma generators and hand pieces in the cosmetic surgery market. This represents an important launch for our Company, as Renuvion Cosmetic Technology demonstrates our strong commitment to physician customers in the cosmetic surgery market by providing them with a brand that was specifically designed to resonate with their patients. Simply stated, the early market response to the Renuvion launch has exceeded our expectations and we could not be happier with positive feedback we have received from our physician customers. Finally, we enhanced our Medical Advisory Board with the appointment of Dr. Diane Duncan, the second expert from the cosmetic surgery market to join our MAB, who along with Dr. Jack Zamora will provide advice and guidance on our long-term clinical and commercial strategies.”

“In addition to the strong operating and financial results we achieved over the first six months of 2018, on July 9th, we announced the divestment and sale of our Core business segment to Specialty Surgical Instrumentation, Inc., a subsidiary of Symmetry Surgical, Inc. We believe this announcement represents a watershed event for our Company; one that we believe is beneficial for all Bovie Medical constituents: our Core business segment customers, our employees and our stockholders. This transaction allows us to focus on our largest, fastest growing market opportunity by leveraging our highly-differentiated J-Plasma/Renuvion technology with the potential to achieve attractive outcomes for physicians and their patients in the cosmetic surgery market. The proceeds from this transaction will significantly enhance our balance sheet, allowing us to pursue this strategy and ultimately achieve strong, sustained and profitable growth for the benefit of our stockholders.”

“As we enter the second half of 2018, we remain focused on executing against our strategic objectives in our Advanced Energy business and expect continued strong adoption of our Renuvion Technology to be the primary driver of growth this year. The transaction with Symmetry is expected to close during the third quarter and following the closing, we plan to host a call with the investment community to update our fiscal year 2018 financial guidance and to share more details about the growth and profitability profile of the remaining Advanced Energy and OEM businesses going forward.”


2


a2017bvxlogoa04.jpg
 
 

Second Quarter 2018 Results:

The following table represents revenue by reportable segment:
 
Three Months Ended
June 30,
 
Increase/Decrease
 
Six Months Ended
June 30,
 
Increase/Decrease
(In thousands)
2018
 
2017
 
$
Change
 
% Change
 
2018
 
2017
 
$
Change
 
% Change
Core
$
7,784

 
$
7,488

 
$
296

 
4.0
%
 
$
14,303

 
$
14,263

 
$
40

 
0.3
 %
Advanced Energy
3,113

 
1,813

 
1,300

 
71.7
%
 
5,742

 
2,420

 
3,322

 
137.3
 %
OEM
578

 
498

 
80

 
16.1
%
 
1,346

 
1,505

 
(159
)
 
(10.6
)%
Total
$
11,475

 
$
9,799

 
$
1,676

 
17.1
%
 
$
21,391

 
$
18,188

 
$
3,203

 
17.6
 %

Total revenue for second quarter 2018 increased $1.7 million, or 17.1%, to $11.5 million, compared to $9.8 million in the second quarter of 2017. Sales of the Company’s J-Plasma/Renuvion generators and handpieces were the primary driver of the increase in total revenue in second quarter 2018, with growth in Core and OEM segment sales contributing modestly to the year-over-year increase in total revenue as well during the second quarter 2018 period. Advanced Energy segment sales increased approximately $1.3 million, or 71.7% year-over-year, to $3.1 million, compared to approximately $1.8 million last year. Core segment sales increased approximately $0.3 million, or 4.0% year-over-year, to $7.8 million, compared to approximately $7.5 million last year. OEM segment sales increased $0.1 million, or 16.1% year-over-year, to $0.6 million, compared to $0.5 million last year.

 
Three Months Ended
June 30,
 
Increase/Decrease
 
Six Months Ended
June 30,
 
Increase/Decrease
(In thousands)
2018
 
2017
 
$
Change
 
% Change
 
2018
 
2017
 
$
Change
 
% Change
Domestic
$
9,700

 
$
8,708

 
$
992

 
11.4
%
 
$
17,673

 
$
15,700

 
$
1,973

 
12.6
%
International
1,775

 
1,091

 
684

 
62.7
%
 
3,718

 
2,488

 
1,230

 
49.4
%
Total
$
11,475

 
$
9,799

 
$
1,676

 
17.1
%
 
$
21,391

 
$
18,188

 
$
3,203

 
17.6
%
Revenue in the United States increased approximately $1.0 million, or 11.4% year-over-year, to $9.7 million, and international revenue increased approximately $0.7 million, or 62.7% year-over-year, to $1.8 million. International sales growth in the second quarter was primarily driven by sales to international distributors in the Company’s Advanced Energy segment.

Gross profit for the second quarter of 2018 increased approximately $1.2 million, or 24.5% year-over-year, to $6.3 million, compared to $5.0 million for second quarter of 2017. The primary drivers of the increase were favorable manufacturing variances partially offset by lower margins in the Advanced Energy segment attributable to product mix.

Operating expenses for the second quarter of 2018 increased approximately $0.2 million, or 3.1% year-over-year, to $6.5 million, compared to $6.3 million for the second quarter of 2017. The year-over-year change in operating expenses was primarily driven by a $0.2 million increase in professional services expense and a $0.1 million increase in research and development expenses, offset partially by a $0.1 million decrease in salaries and related expense.

Loss from operations for second quarter 2018 was $0.3 million, compared to a loss from operations of $1.3 million for the comparable period last year.

3


a2017bvxlogoa04.jpg
 
 

Net loss for second quarter 2018 was $0.3 million, or $0.01 per diluted share, compared to a loss of $1.3 million, or $0.04 per diluted share, for the second quarter of 2017.

As of June 30, 2018, the Company had cash and equivalents of $8.5 million as compared to $10.7 million as of December 31, 2017. The Company had working capital of $16.0 million as of June 30, 2018 as compared to $16.6 million as of December 31, 2017.

Six Months 2018 Results:

Total revenue for the six months ended June 30, 2018 increased $3.2 million, or 17.6%, to $21.4 million, compared to $18.2 million in the six months ended June 30, 2017. Total revenue growth was driven by a 137.3% increase in Advance Energy sales and a 0.3% increase in Core sales, and was partially offset by a 10.6% decrease in OEM sales.

Net loss for the six months ended June 30, 2018 was $1.2 million, or $0.04 per diluted share, compared to a loss of $3.0 million, or $0.10 per diluted share, for the six months ended June 30, 2017.

2018 Outlook:

The Company plans to update its financial guidance for fiscal year 2018 following the close of the divestment and sale of the Core business segment to Specialty Surgical Instrumentation, Inc., a subsidiary of Symmetry Surgical, Inc. which is expected to occur in the third quarter of 2018.



4


a2017bvxlogoa04.jpg
 
 

Investor Relations Contact:

Westwicke Partners on behalf of Bovie Medical Corporation
Mike Piccinino, CFA
443-213-0500
investor.relations@boviemed.com

About Bovie Medical Corporation:

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma/Renuvion technology utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, and minimal invasiveness. The new J-Plasma/Renuvion handpieces with Cool-Coag™ technology deliver the precision of helium plasma energy, the power of traditional monopolar coagulation and the efficiency of plasma beam coagulation - enabling thin-layer ablation and dissection and fast coagulation with a single instrument, minimizing instrument exchange and allowing a surgeon to focus on their patient and their procedures. With Cool-Coag technology, the new J-Plasma/Renuvion handpieces can deliver three distinctly different energy modalities - further increasing the utility and versatility of the system. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, IDS™ and DERM™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Bovie Medical Corporation website at www.boviemedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2017 and subsequent Form 10-Q filings. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

5


a2017bvxlogoa04.jpg
 
 
BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited) (In thousands, except per share data)


 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2018
 
2017
 
2018
 
2017
Sales
$
11,475

 
$
9,799

 
$
21,391

 
$
18,188

Cost of sales
5,198

 
4,757

 
10,124

 
8,920

Gross profit
6,277

 
5,042

 
11,267

 
9,268

Other costs and expenses:
 
 
 
 
 
 
 
Research and development
816

 
696

 
1,378

 
1,405

Professional services
681

 
480

 
1,187

 
870

Salaries and related costs
2,118

 
2,243

 
4,234

 
4,703

Selling, general and administrative
2,929

 
2,929

 
5,599

 
5,333

Total other costs and expenses
6,544

 
6,348

 
12,398

 
12,311

Loss from operations
(267
)
 
(1,306
)
 
(1,131
)
 
(3,043
)
Interest expense, net
(38
)
 
(36
)
 
(72
)
 
(67
)
Change in fair value of derivative liabilities
46

 
38

 
20

 
126

Total other income (expense), net
8

 
2

 
(52
)
 
59

Loss before income taxes
(259
)
 
(1,304
)
 
(1,183
)
 
(2,984
)
Income tax expense
13

 
4

 
24

 
9

Net loss
$
(272
)
 
$
(1,308
)
 
$
(1,207
)
 
$
(2,993
)
 
 
 
 
 
 
 
 
Loss per share
 
 
 
 
 
 
 
Basic
$
(0.01
)
 
$
(0.04
)
 
$
(0.04
)
 
$
(0.10
)
Diluted
$
(0.01
)
 
$
(0.04
)
 
$
(0.04
)
 
$
(0.10
)
 
 
 
 
 
 
 
 
Weighted average number of shares outstanding - basic
32,890

 
30,860

 
32,884

 
30,860

Weighted average number of shares outstanding - dilutive
32,890

 
30,860

 
32,884

 
30,860



6


a2017bvxlogoa04.jpg
 
 
BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited) (In thousands, except share and per share data)


 
June 30,
2018
 
December 31,
2017
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
7,875

 
$
9,949

Restricted cash
660

 
719

Trade accounts receivable, net of allowance of $180 and $204
5,592

 
4,857

Inventories, net
7,533

 
6,526

Prepaid expenses and other current assets
568

 
496

Total current assets
22,228

 
22,547

Property and equipment, net
6,314

 
6,408

Brand name and trademark
1,510

 
1,510

Purchased technology and license rights, net
235

 
179

Goodwill
185

 
185

Deposits
115

 
92

Other assets
67

 
67

Total assets
$
30,654

 
$
30,988

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
2,745

 
$
1,583

Accrued severance and related
439

 
1,242

Accrued payroll
394

 
447

Current portion of mortgage note payable
239

 
239

Accrued and other liabilities
2,420

 
2,462

Total current liabilities
6,237

 
5,973

Mortgage note payable, net of current portion
2,335

 
2,455

Note payable
140

 
140

Deferred tax liability
368

 
368

Derivative liabilities

 
20

Total liabilities
9,080

 
8,956

STOCKHOLDERS’ EQUITY
 
 
 
Common stock, $0.001 par value; 75,000,000 shares authorized; 33,055,131 issued and 32,912,556 outstanding as of June 30, 2018 and 75,000,000 shares authorized; 33,021,170 issued and 32,878,091 outstanding as of December 31, 2017, respectively
33

 
33

Additional paid-in capital
51,244

 
50,495

Accumulated deficit
(29,703
)
 
(28,496
)
Total stockholders’ equity
21,574

 
22,032

Total liabilities and stockholders’ equity
$
30,654

 
$
30,988





7


a2017bvxlogoa04.jpg
 
 
BOVIE MEDICAL CORPORATION
RECONCILIATION OF GAAP NET INCOME/(LOSS) RESULTS TO NON-GAAP ADJUSTED EBITDA/(LOSS)
(Unaudited) (In thousands)


Use of Non-GAAP Financial Measures

We present these non-GAAP measures because we believe these measures are useful indicators of our operating performance. Our management uses these non-GAAP measures principally as a measure of our operating performance and believes that these measures are useful to investors because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that these measures are useful to our management and investors as a measure of comparative operating performance from period to period.

The Company has presented the following non-GAAP financial measures in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income/(loss) (GAAP) plus income tax expense, interest expense, net, depreciation and amortization, stock-compensation expense, and changes in value of derivative liabilities.
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2018
 
2017
 
2018
 
2017
Net loss GAAP Basis
$
(272
)
 
$
(1,308
)
 
$
(1,207
)
 
$
(2,993
)
Interest expense, net
38

 
36

 
72

 
67

Income tax expense
13

 
4

 
24

 
9

Depreciation and amortization
172

 
178

 
371

 
356

Stock based compensation
377

 
182

 
749

 
341

Change in fair value of derivative liabilities
(46
)
 
(38
)
 
(20
)
 
(126
)
Adjusted EBITDA
282

 
(946
)
 
(11
)
 
(2,346
)


8

View differences made from one to another to evaluate Bovie Medical Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bovie Medical Corp.

Continue

Assess how Bovie Medical Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bovie Medical Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Bovie Medical Corp provided additional information to their SEC Filing as exhibits

Ticker: BVX
CIK: 719135
Form Type: 8-K Corporate News
Accession Number: 0000719135-18-000054
Submitted to the SEC: Wed Aug 01 2018 4:11:04 PM EST
Accepted by the SEC: Wed Aug 01 2018
Period: Wednesday, August 1, 2018
Industry: Surgical And Medical Instruments And Apparatus
Events:
  1. Earnings Release
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bvx/0000719135-18-000054.htm